Drs Yancy and O'Gara discuss the new definition of hypertension and when clinical judgment will come into play.

Sports preparticipation screening, cell therapy in PAD, exercise, supplements, and US healthcare policy are reviewed in this week’s podcast.

Dual antiplatelet therapy duration after coronary stenting remains debatable. Drs Harrington, Batchelor, and O'Donoghue discuss some of the data from TCT and predict the demise of bare metal stents.

Cardiac intensive care units have evolved rapidly in recent years. Drs Barsness and Acharya discuss unique training and resource requirements for a model CICU.

Drs Harrington, Maron, and Patel discuss the ORBITA trial, which compared coronary stenting with sham percutaneous coronary intervention for angina relief. Why did ORBITA cause so much buzz?

New hypertension guidelines, BP measurement, DOACs during device surgery, a CANTOS substudy, and conflicting data on the heart-failure readmissions reduction program are discussed this week.

Dr Walton-Shirley reviews the key updates in the 2017 ACC/AHA guidelines for the Prevention, Detection, Evaluation and Management of High Blood Pressure with the guideline chair.

Drs Harrington, Batchelor, and O'Donoghue discuss the implications of the TCT late-breaking CULPRIT SHOCK trial testing culprit-only vs multivessel revascularization in unstable patients in cardiogenic shock.

Dr John Mandrola discusses PCI in stable CAD, MR, exercise, AHA preview, and celebrities at medical meetings in this week's podcast.

This narrated case proves that no matter the indication for the echo, it pays to be thorough.